Evercore ISI downgraded Edwards Lifesciences (EW) to In Line from Outperform with a price target of $77, down from $80. The 8%-10% TAVR growth outlook assumes Edwards growing inline with the market, but this won’t allay the bear debate on risks to estimates on share shifts due to Boston Scientific’s (BSX) entry, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences price target raised to $84 from $78 at Truist
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Edwards Lifesciences downgraded to Mixed from Positive view at OTR Global
- Edwards Lifesciences price target raised by $2 at Truist, here’s why
- Edwards Lifesciences just downgraded at Citi, here’s why
